Bulk Inquiry
NRX 194204
- NRX 4204 - VTP 194204 - AGN 194204 - AGN 4204
- Optical Purity: Optically pure
- Soluble in DMSO
- MF: C24H32O2
- MW: 352.51
Description
NRX 194204 (AGN194204) is a highly potent retinoid X receptor (RXR) agonist with strong activity at RXRα, RXRβ and RXRγ and minimal activity at retinoic acid receptors. It is used to selectively activate RXR-dependent transcriptional programs.
RXR receptors form homodimers and heterodimers with several nuclear receptors, including PPAR, LXR, FXR and RAR, thereby influencing metabolism, inflammation, differentiation and neurobiology. NRX 194204 is valuable where RXR-selective pharmacology is required without direct RAR activation.
Key Features
- Highly potent RXR agonist
- Reported Kd values: 0.4 nM for RXRα, 3.6 nM for RXRβ and 3.8 nM for RXRγ
- High selectivity over RARα, RARβ and RARγ
- Activates RXR-dependent nuclear receptor signaling
Applications
- RXR nuclear receptor pharmacology
- Retinoid signaling and transcription assays
- Metabolic and inflammatory pathway research
- Neurodegeneration and differentiation model studies
More Information
| Parent CAS No. | 220619-73-8 |
|---|---|
| Chemical Name | (2E,4E)-3-Methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid |
| SMILES | C1C(C)(C)C2C=C([C@@]3(C)C[C@@]3([H])/C=C/C(/C)=C/C(=O)O)C=CC=2C(C)(C)C1 |&1:7,10,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1 |
| InChiKey | BOOOLEGQBVUTKC-NVQSDHBMSA-N |
| CID | 9863341 |
| Short Description | RXR agonist |
References
- K. Liby et al. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res. 2007 Oct 15;13(20):6237-43.
- V. Vuligonda et al. Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. J Med Chem. 2001 Jul 5;44(14):2298-303.
- R. AS Chandraratna et al. Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis. Am J Transl Res. 2016; 8(2): 1016–1026.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1173 | BMS 270394 |
From $181.50 |
| 1194 | BMS 189961 |
From $159.50 |
| 1241 | CH 55 |
From $99.00 |
| 1242 | LE 135 |
From $132.00 |
| 1700 | Bexarotene |
From $71.50 |
| 2637 | LY 2955303 dihydrochloride |
From $159.50 |
| 2679 | AR7 |
From $99.00 |
| 3003 | HX600 |
From $165.00 |
| 3727 | SR11237 |
From $132.00 |
| 4017 | LG100268 |
From $104.50 |
